2. Search Result
Search Result
Results for "

anti-leukemia

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

3

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18714
    BRD7116

    		Bacterial Others
    BRD7116 competitively binds to bacterial DNA gyrase, exhibits an EC50 of 200 nM for LSCe cells, with cell-non-autonomous anti-leukemia activity.
    BRD7116
  • HY-114162A
    VTP50469 fumarate
    4 Publications Verification

    		 Epigenetic Reader Domain Apoptosis Cancer
    VTP50469 fumarate is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 fumarate has potently anti-leukemia activity .
    VTP50469 fumarate
  • HY-114162
    VTP50469
    4 Publications Verification

    		 Epigenetic Reader Domain Apoptosis Cancer
    VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 has potently anti-leukemia activity .
    VTP50469
  • HY-N1112
    Uncargenin C

    		Others Cancer
    Uncargenin C is a triterpenoid, which can be isolated from Uncaria rhychophyllo Miq. Jacks. The intermediate of Uncargenin C has anti-leukemia activity, but not itself .
    Uncargenin C
  • HY-149805
    Anticancer agent 110

    		Apoptosis Cancer
    Anticancer agent 110 is an anticancer agent with in vitro anticancer activity and excellent anti-leukemia potency. Anticancer agent 110 is highly cytotoxic to K-562 lineage chronic myelogenous leukemia cells at nanomolar concentrations. Anticancer agent 110 causes DNA damage and leads to apoptosis .
    Anticancer agent 110
  • HY-14942A
    Berubicin hydrochloride

    RTA 744; WP 744; WP 769 hydrochloride

    		 Apoptosis Cancer
    Berubicin hydrochloride (RTA 744) is a Doxorubicin (HY-15142A) analogue. Berubicin hydrochloride triggers apoptosis and cell killing in NB cells by activating proapoptotic mediators. Berubicin hydrochloride has proapoptotic and anti-leukemia activities. Berubicin hydrochloride can be used for cancer research .
    Berubicin hydrochloride
  • HY-W077242
    1,4-Anthraquinone

    		DNA/RNA Synthesis Cancer
    1,4-Anthraquinone is a potent anticancer agent. 1,4-Anthraquinone blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of cancer cells. 1,4-Anthraquinone can be used to research anti-leukemia .
    1,4-Anthraquinone
  • HY-139193
    TH1760

    		Others Cancer
    TH1760 is an inhibitor of NUDIX-type 15 (NUDT15) with an IC50 value of 25 nM. TH1760 sensitizes cells to 6-thioguanine by enhancing the accumulation of 6-thio- (d) GTP in nucleic acids. TH1760 enhances the anti-leukemia effect of thiopurine .
    TH1760
  • HY-124069
    M-525

    		Epigenetic Reader Domain Cancer
    M-525 is a first-in-class, highly potent, irreversible and covalent menin-MLL protein-protein interaction inhibitor. M-525 binds to menin with an IC50 of 3 nM and achieves low nanomolar potencies in cell growth inhibition and in suppression of MLL regulated gene expression in MLL leukemia cells. Anti-leukemia activity .
    M-525
  • HY-13765
    6-Thioguanine
    Maximum Cited Publications
    6 Publications Verification

    Thioguanine; 2-Amino-6-purinethiol

    		 SARS-CoV Deubiquitinase DNA Methyltransferase Autophagy Apoptosis Endogenous Metabolite Infection Inflammation/Immunology Cancer
    6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (PLpros) and also potently inhibits USP2 activity, with IC50s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.
    6-Thioguanine
  • HY-150109
    Purinostat mesylate

    		HDAC Apoptosis Cancer
    Purinostat mesylate is a selective inhibitor of HDAC. Purinostat mesylate inhibits class I and class IIb HDACs with IC50s from 0.81 to 11.5 nM. Purinostat mesylate induces apoptosis and affects cell cycle of LAMA84 and 188 BL-2 cells, and shows potently anti-leukemia effects in vivo. Purinostat mesylate can be used for the research of lymphoblastic leukemia .
    Purinostat mesylate
  • HY-N0093
    Ancitabine hydrochloride
    1 Publications Verification

    Cyclocytidine hydrochloride; Cyclo-CMP hydrochloride; Cyclo-C

    		 Autophagy CMV Cancer
    Ancitabine (hydrochloride) is an important antileukemia drugs.
    Ancitabine hydrochloride
  • HY-N0093A
    Ancitabine

    Cyclocytidine; Cyclo-CMP

    		 Others Cancer
    Ancitabine is an antileukemia drug .
    Ancitabine
  • HY-149539
    PLM-101

    		FLT3 RET Cancer
    PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3; and it inhibits the PI3K and Ras/ERK pathways, resulting in anti-leukemia activity. PLM-101 has anti-tumor efficacy in a mouse MV4-11 flank xenograft model (dose: 3, 10 mg/kg; po) and an allogeneic xenograft mouse model (dose: 40 mg/kg; po) .
    PLM-101
  • HY-16273A
    L-778123 hydrochloride
    1 Publications Verification

    		 Farnesyl Transferase Cancer
    L-778123 hydrochloride is a dual inhibitor of FPTase and GGPTase-I, with IC50 values of 2 nM and 98 nM respectively.
    L-778123 hydrochloride
  • HY-16273
    L-778123

    		Farnesyl Transferase Cancer
    L-778123 is a dual FPTase and GGPTase-I inhibitor, with IC50s of 2 nM and 98 nM respectively .
    L-778123
  • HY-141844
    HDAC/BET-IN-1

    		HDAC Cancer
    HDAC/BET-IN-1 displays submicromolar inhibitory activity against HDAC1 and 6 (IC50 = 0.163 μM and 0.067 μM), and BRD4 (Ki = 0.076 μM), and possess potent antileukemia activity.
    HDAC/BET-IN-1
  • HY-111380
    EHT 1610
    1 Publications Verification

    		 DYRK Neurological Disease
    EHT 1610 is a potent inhibitor of DYRK, with IC50s of 0.36 nM (DYRK1A), 0.59 nM (DYRK1B), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis - .
    EHT 1610
  • HY-154971
    Ara-SH

    		Apoptosis Cancer
    Ara-SH is a Cytarabine mercaptopropionic acid-substituted derivative. Ara-SH is used as the trigger to fabricate a smart Cytarabine and Venetoclax-coloaded nanoparticle (AV-NP) through self-assembly. Ara-SH exhibits remarkable synergistic antileukemia effects in vitro and in vivo .
    Ara-SH
  • HY-147868
    DC-CPin711

    		Epigenetic Reader Domain Apoptosis Cancer
    DC-CPin711 is a potent and selective inhibitor of CREB-binding protein (CBP) bromodomain with an IC50 of 0.0626 μM. DC-CPin711 arrests cell cycle at G1 phase and induces apoptosis .
    DC-CPin711

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: